Sol-Gel Technologies Ltd. (SLGL): Capital Expenditures
$47.0K
Year ended 2025-12-31
-35.0%
3-year compound annual growth
-36.3%
5-year compound annual growth
-16.7%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $47.0K | n/m | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $2.0K | -98.5% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $134.0K | -21.6% | 2026-03-19, From 2023-01-01 |
| 2022-12-31 | $171.0K | +19.6% | 2025-04-29, From 2022-01-01 |
| 2021-12-31 | $143.0K | -68.2% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $449.0K | -24.8% | 2023-03-10, From 2020-01-01 |
| 2019-12-31 | $597.0K | -43.3% | 2022-04-07, From 2019-01-01 |
| 2018-12-31 | $1.05M | -45.4% | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $1.93M | +400.0% | 2020-03-24, From 2017-01-01 |
| 2016-12-31 | $385.0K | +32.3% | 2019-03-21, From 2016-01-01 |
| 2015-12-31 | $291.0K | n/a | 2018-03-26, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $47.0K | n/m |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $5.0K | -64.3% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $16.0K | -92.8% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $246.0K | -63.4% |
| uniQure N.V. (QURE) | 2025-12-31 | $439.0K | -87.0% |
| Alumis Inc. (ALMS) | 2025-12-31 | $653.0K | -62.3% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $1.04M | -67.0% |
| Celularity Inc (CELU) | 2024-12-31 | $161.0K | -84.6% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $0 | -100.0% |
Compare SLGL, EVFM, CASIF, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗